HCWB
MaterialsHCW Biologics Inc
Live · NASDAQ · May 8, Close
What's Moving HCWB Today?
No stock-specific AI insight has been generated for HCWB yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
HCWB News
20 articles- HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of QuorumYahoo Finance·Apr 30, 2026
- HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid TumorsYahoo Finance·Apr 27, 2026
- HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial ResultsYahoo Finance·Mar 31, 2026
- HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion ImmunotherapeuticYahoo Finance·Mar 17, 2026
- BC-Most Active StocksYahoo Finance·Mar 16, 2026
- HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science AdvancesYahoo Finance·Mar 16, 2026
- HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination LetterYahoo Finance·Mar 2, 2026
- Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsightYahoo Finance·Feb 19, 2026
- HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ RulesYahoo Finance·Feb 18, 2026
- HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture TrimmuneYahoo Finance·Feb 13, 2026
- HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq RulesYahoo Finance·Nov 19, 2025
- HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune DiseaseYahoo Finance·Nov 18, 2025
- HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial ResultsYahoo Finance·Nov 14, 2025
- HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of CancerYahoo Finance·Nov 10, 2025
- HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual MeetingYahoo Finance·Nov 7, 2025
- HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” SegmentYahoo Finance·Oct 22, 2025
- HCW Biologics to Participate in the 2025 Maxim Growth SummitYahoo Finance·Oct 16, 2025
- HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of CancerYahoo Finance·Oct 16, 2025
- HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager ProgramYahoo Finance·Sep 30, 2025
- HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity FinancingYahoo Finance·Sep 18, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About HCW Biologics Inc
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.